The Food and Drug Administration approved BESPONSA based on the results of the clinical trial that showed treatment with BESPONSA compared to chemotherapy improved complete remission (CR) rates (36% vs 17%), length of CR (8.0 months vs 4.9 months), and minimal residual disease–negative CR rates (90% vs 32%).. Recommended Dosage. Pre-medicate before each dose [see Dosage and Administration (2.2)]. For the first cycle, the recommended total dose of BESPONSA for all patients is 1.8 mg/m 2 per cycle, administered as 3 divided doses on Day 1 (0.8 mg/m 2), Day 8 (0.5 mg/m 2), and Day 15 (0.5 mg/m 2).. © 2019 Canadian-Pill-Identifier.com © All Rights Reserved. Drug Product Database and Data Extract. Health Canada, 2015. Adapted and reproduced with permission from . ‡ Patient Advocacy Groups (or individual patients and caregivers when there is no patient group) and Clinicians who are registered with pCODR are eligible to provide Input and Feedback.. BESPONSA is supplied as a 0.9 mg single-dose vial. Each vial is reconstituted with 4 mL of Sterile Water for Injection, USP, to obtain a concentration of Please refer to the full Prescribing Information for complete Dosage and Administration instructions. Administration3,5 (CPT®) The information provided in this document is intended for informational purposes only, and is not a comprehensive . 8 (0.5 mg/m 2), and Day 15 (0.5 mg/m ) Cycle 1 is 3 weeks in duration, but may be extended to 4 weeks if the patient achieves CR or CRi, and/or to allow recovery from toxicity.